insulin aspart vs insulin glulisine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin aspart · NovoLog

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

insulin glulisine · Apidra

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00290927 · Phase 3 · completed

The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.

Reported efficacy

Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)

Result source: NCT00135057

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin aspartinsulin glulisine
HbA1c, change-1.2% vs -1.3%vs IGlaronce daily · wk 52 · n 744NCT00972283
19 other results
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.9% vs -1.7% wk 26 · n 197 · Phase 3 · primary NCT01513590
  • -1.4% vs -1.4% BID · wk 26 · n 280 · Phase 3 · primary NCT01059812
  • -0.7% vs 0.1% wk 26 · n 88 · Phase 3 · primary NCT01388361
  • -1.4% vs -1.2% OD · wk 26 · n 147 · Phase 3 · primary NCT01272193
  • -1.0% vs -1% once daily · wk 26 · n 230 · Phase 3 · primary NCT01045447
  • -1.6% vs -1.7% wk 26 · n 266 · Phase 3 · primary NCT01045707
  • -1.3% vs -1.3% wk 26 · n 224 · Phase 3 · primary NCT01009580
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -1.1% once daily · wk 78 · n 744 · Phase 3 · secondary NCT00972283
  • -1.4% vs -1.3% wk 53 · n 266 · Phase 3 · secondary NCT01045707
  • -1.2% vs -1.3% wk 32 · n 164 · Phase 4 · primary NCT02453685
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.5% n 115 · Phase 2 · primary NCT01194258
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
Body weight, change (kg)2.7 vs 2.2vs Insulin Glarginewk 26 · n 291NCT04880850
11 other results
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 2.8 vs 2 wk 26 · n 196 · Phase 3 · secondary NCT01513590
  • -1 vs 0.1 wk 26 · n 87 · Phase 3 · secondary NCT01388361
  • 0.7 vs 0.7 OD · wk 26 · n 147 · Phase 3 · secondary NCT01272193
  • 1.1 vs 1.4 BID · wk 26 · n 279 · Phase 3 · secondary NCT01059812
  • 0.9 vs 0.3 wk 16 · n 117 · Phase 3 · secondary NCT01474538
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
  • 1.5 vs 1.6 n 115 · Phase 2 · secondary NCT01194258
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 0.1 vs -0.1 wk 6 · n 33 · Phase 2 · secondary NCT00842361
0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
HbA1c below 7%44% vs 20%vs Metformin, Insulin Detemir, Insulin Aspartwk 26 · n 46NCT0196697822.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
Fasting plasma glucose, change-1.8 vs -1.6vs Insulin Glarginewk 26 · n 283NCT04880850
5 other results
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -4.4 vs -3.0 wk 26 · n 195 · Phase 3 · secondary NCT01513590
  • -0.1 vs -1.2 wk 26 · n 86 · Phase 3 · secondary NCT01388361
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
—Not posted · NCT00135057
3-point MACE (% with event)—Not posted · NCT01467323—Not posted · NCT00135057

HbA1c, change

insulin aspart
-1.2% vs -1.3%vs IGlaronce daily · wk 52 · n 744NCT00972283
19 other results
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.9% vs -1.7% wk 26 · n 197 · Phase 3 · primary NCT01513590
  • -1.4% vs -1.4% BID · wk 26 · n 280 · Phase 3 · primary NCT01059812
  • -0.7% vs 0.1% wk 26 · n 88 · Phase 3 · primary NCT01388361
  • -1.4% vs -1.2% OD · wk 26 · n 147 · Phase 3 · primary NCT01272193
  • -1.0% vs -1% once daily · wk 26 · n 230 · Phase 3 · primary NCT01045447
  • -1.6% vs -1.7% wk 26 · n 266 · Phase 3 · primary NCT01045707
  • -1.3% vs -1.3% wk 26 · n 224 · Phase 3 · primary NCT01009580
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -1.1% once daily · wk 78 · n 744 · Phase 3 · secondary NCT00972283
  • -1.4% vs -1.3% wk 53 · n 266 · Phase 3 · secondary NCT01045707
  • -1.2% vs -1.3% wk 32 · n 164 · Phase 4 · primary NCT02453685
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.5% n 115 · Phase 2 · primary NCT01194258
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
insulin glulisine
-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698

Body weight, change (kg)

insulin aspart
2.7 vs 2.2vs Insulin Glarginewk 26 · n 291NCT04880850
11 other results
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 2.8 vs 2 wk 26 · n 196 · Phase 3 · secondary NCT01513590
  • -1 vs 0.1 wk 26 · n 87 · Phase 3 · secondary NCT01388361
  • 0.7 vs 0.7 OD · wk 26 · n 147 · Phase 3 · secondary NCT01272193
  • 1.1 vs 1.4 BID · wk 26 · n 279 · Phase 3 · secondary NCT01059812
  • 0.9 vs 0.3 wk 16 · n 117 · Phase 3 · secondary NCT01474538
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
  • 1.5 vs 1.6 n 115 · Phase 2 · secondary NCT01194258
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 0.1 vs -0.1 wk 6 · n 33 · Phase 2 · secondary NCT00842361
insulin glulisine
0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result

HbA1c below 7%

insulin aspart
44% vs 20%vs Metformin, Insulin Detemir, Insulin Aspartwk 26 · n 46NCT01966978
insulin glulisine
22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085

Fasting plasma glucose, change

insulin aspart
-1.8 vs -1.6vs Insulin Glarginewk 26 · n 283NCT04880850
5 other results
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -4.4 vs -3.0 wk 26 · n 195 · Phase 3 · secondary NCT01513590
  • -0.1 vs -1.2 wk 26 · n 86 · Phase 3 · secondary NCT01388361
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
insulin glulisine
—Not posted · NCT00135057

3-point MACE (% with event)

insulin aspart
—Not posted · NCT01467323
insulin glulisine
—Not posted · NCT00135057
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. insulin aspart: 6 of 6 rows · insulin glulisine: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin aspart
Rows use multiple source trials
insulin glulisine
Rows use multiple source trials
Daily Plasma Glucose Change mg/dL
absolute change · mmol/L
9.44 vs 8.49 Insulin Detemir mmol/L @ 26wk*a,b
NCT00998335 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 170 mg/dL as posted
-0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk*a,b
NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted
HbA1c
absolute value · percentage points
6.7% (n=22) vs 6.9% (n=30) Insulin Detemir @ 26wka,b
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wka,b
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
Dropout rate
0%once weeklyc
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT02453685 · Phase 4 · registry result, not featured evidence
13.9%
NCT01165684 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
5.5%
NCT04880850 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
15.4%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
12.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
—
NCT01474538 · Phase 3 · registry result, not featured evidence
5.1%
NCT01513590 · Phase 3 · registry result, not featured evidence
13.6%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
6.6%IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
6.4%IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
6.8%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
13.1%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
18.1%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
15.5%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
17.7%
NCT01045707 · Phase 3 · registry result, not featured evidence
12.1%
NCT01009580 · Phase 3 · registry result, not featured evidence
—
NCT01194258 · Phase 2 · registry result, not featured evidence
3%
NCT00842361 · Phase 2 · registry result, not featured evidence
23.5%Lantus/Apidra-1c
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—once weeklyc
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02453685 · Phase 4 · registry result, not featured evidence
0.5%
NCT01165684 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
—
NCT00591227 · Phase 4 · registry result, not featured evidence
—
NCT04880850 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.2%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
1.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
—
NCT01474538 · Phase 3 · registry result, not featured evidence
1%
NCT01513590 · Phase 3 · registry result, not featured evidence
5.7%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
—IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
—IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
0.7%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
3.2%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
4.1%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
0%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
1.9%
NCT01045707 · Phase 3 · registry result, not featured evidence
1.8%
NCT01009580 · Phase 3 · registry result, not featured evidence
—
NCT01194258 · Phase 2 · registry result, not featured evidence
—
NCT00842361 · Phase 2 · registry result, not featured evidence
2.6%Lantus/Apidra-1c
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
Serious AEs
22.5%once weeklyc
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
8.4%
NCT02453685 · Phase 4 · registry result, not featured evidence
9.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
0%
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
7.6%
NCT04880850 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
5.2%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
7.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
11.8%
NCT01474538 · Phase 3 · registry result, not featured evidence
6.6%
NCT01513590 · Phase 3 · registry result, not featured evidence
4.6%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
0.7%IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
4.3%IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
3.4%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
8.2%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
18.5%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
4.3%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
11.3%
NCT01045707 · Phase 3 · registry result, not featured evidence
8.5%
NCT01009580 · Phase 3 · registry result, not featured evidence
6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
3%
NCT00842361 · Phase 2 · registry result, not featured evidence
11.9%Lantus/Apidra-1c
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
6.5%Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
once weeklyc
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 22 more results
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 12.7%
headache 7.2%
arthralgia 6.6%
NCT02453685 · Phase 4 · registry result, not featured evidence
nasopharyngitis 8.1%
headache 5.1%
influenza 5.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 10.4%
nasopharyngitis 8.9%
headache 6.7%
NCT01680341 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.9%
influenza 9%
upper respiratory tract infection 7.5%
NCT01680341 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
rhinitis allergic 4.2%
back pain 3.4%
NCT01474538 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.7%
NCT01513590 · Phase 3 · registry result, not featured evidence
nausea 20.7%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 9%
nasopharyngitis 6%
NCT01365507 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 10.7%
nasopharyngitis 7.9%
NCT01365507 · Phase 3 · registry result, not featured evidence
OD
nasopharyngitis 22.4%
diabetic retinopathy 5.4%
NCT01272193 · Phase 3 · registry result, not featured evidence
BID
nasopharyngitis 18.3%
upper respiratory tract infection 7.5%
diabetic retinopathy 6.8%
NCT01059812 · Phase 3 · registry result, not featured evidence
once daily
nasopharyngitis 16.5%
upper respiratory tract infection 16.3%
headache 9.4%
NCT00972283 · Phase 3 · registry result, not featured evidence
once daily
headache 8.7%
nasopharyngitis 7.4%
diarrhoea 5.2%
NCT01045447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
hypertension 7.5%
back pain 6%
NCT01045707 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11.6%
upper respiratory tract infection 7.6%
headache 5.8%
NCT01009580 · Phase 3 · registry result, not featured evidence
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
nasopharyngitis 9.1%
supraventricular extrasystoles 6.1%
NCT00842361 · Phase 2 · registry result, not featured evidence
c
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bAssessment timepoints differ: 26 weeks versus 24 weeks.
  3. cPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin aspart

HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Treatment Failure 7.4% (n=46) vs 16.1% (n=44) Metformin, Insulin Detemir, Insulin Aspart @ 13wk
responder rate · % of participants
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe Hypoglycemia 42.3% (n=168) vs 56.3% (n=167) insulin glargine + insulin aspart @ 32wk
responder rate · % of participants
NCT02453685 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 19.2% (n=193) vs 56.3% (n=183) insulin aspart @ 10wk
absolute value · percentage points
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
45.1% (n=195) vs 65.4% (n=188) insulin aspart @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 7.1 vs 6.7 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
7.1 vs 7 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
7.12 vs 7.01 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Postprandial Glucose Increment 2.3 vs 1.4 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
1.9 vs 1.5 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
1.64 vs 1.28 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Body Weight 89.32 vs 89.8 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
BMI 31.86 vs 32.03 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
Hepatic Fat Fraction NA vs 6.7% (n=30) Insulin Detemir @ 13wk
percent change · % of baseline
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
5.9% (n=22) vs 8.4% (n=30) Insulin Detemir @ 26wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
Fasting Plasma Glucose NA vs 5.83 Insulin Detemir mmol/L @ 13wk
absolute change · mmol/L
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
show 6 more results
6.44 vs 4.94 Insulin Detemir mmol/L @ 26wk*
NCT00998335 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 116 mg/dL as posted
-1.75 vs -1.61 Insulin Glargine mmol/L @ 26wk
NCT04880850 · Phase 3 · registry result, not featured evidence
-2.99 vs -1.57 BIAsp 30 mmol/L @ 26wkBID
NCT02762578 · Phase 3 · registry result, not featured evidence
-2 vs -4.4 Biphasic Insulin Aspart 30 mmol/L @ 4.14wktwice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
-4.44 vs -3.03 BIAsp 30 mmol/L @ 26wk
NCT01513590 · Phase 3 · registry result, not featured evidence
-0.14 vs -1.23 IDeg mmol/L @ 26wk
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
BMI NA vs -0.4 Insulin Detemir kg @ 13wk
absolute change · kg
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
0.2 vs 0.3 Insulin Detemir kg @ 26wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3 · registry result, not featured evidence

+ 40 further endpoints in the CSV export.

insulin glulisine

HbA1c Less Than 7% 43.3% (n=187) vs 38.6% (n=189) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
44.1% (n=195) vs 38.1% (n=197) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c -2.3% (n=138) vs -1.97% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
Absolute change in HbA1c from baseline
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe or BG Confirmed Hypoglycemia 23% (n=183) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
25% (n=180) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
Symptomatic Hypoglycemia 8.19% (n=49) vs 7.68% (n=57) Insulin Glargine+Metformin+Glimepiride
event rate · % of participants
NCT00360698 · Phase 4 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · insulin glulisine's landscape